SCLC - Small cell lung cancer
An immunohistochemical study of cyclin dependent kinase 5 (CDK5) expression in non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker
8
Synergistic Anticancer Activity of Topotecan— Cyclin Dependent Kinase Inhibitor Combinations against Drug Resistant Small Cell Lung Cancer (SCLC) Cell Lines
7
Langerhans dendritic cells, tobacco smoke and lung tumours
247
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
11
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
16
Pathological transition as the arising mechanism for drug resistance in lung cancer
13
Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study
7
Clinical trials in advanced stage lung cancer: a survey of patients' opinion about their treatment
8
Original Article RET mutation and expression in small cell lung cancer
7
ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer
12
Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases
9
MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs
12
Determinants of health-related quality of life in patients with small cell lung cancer: a systematic PubMed review and meta-analysis
5
The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis
8
Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway
13
Gender Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years
13
Studying combined effects of chemotherapy and radiotherapy on blood cell counts in lung cancer patients
8
<p>Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan</p>
12
The relationship between <em>UGT1A1</em> gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
9
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
8